Highland Capital Management LLC Purchases New Stake in Option Care Health, Inc. (NASDAQ:OPCH)

Highland Capital Management LLC purchased a new stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 10,271 shares of the company’s stock, valued at approximately $238,000.

Several other institutional investors also recently bought and sold shares of OPCH. Pacer Advisors Inc. raised its stake in shares of Option Care Health by 2.2% in the 4th quarter. Pacer Advisors Inc. now owns 25,483 shares of the company’s stock valued at $591,000 after acquiring an additional 537 shares during the period. KBC Group NV increased its holdings in Option Care Health by 46.4% in the 4th quarter. KBC Group NV now owns 7,337 shares of the company’s stock valued at $170,000 after purchasing an additional 2,324 shares in the last quarter. Blue Trust Inc. raised its position in Option Care Health by 16.9% in the fourth quarter. Blue Trust Inc. now owns 4,703 shares of the company’s stock valued at $109,000 after purchasing an additional 681 shares during the period. Whalen Wealth Management Inc. acquired a new position in shares of Option Care Health during the fourth quarter worth about $253,000. Finally, Avior Wealth Management LLC lifted its stake in shares of Option Care Health by 4.8% during the fourth quarter. Avior Wealth Management LLC now owns 25,466 shares of the company’s stock worth $591,000 after purchasing an additional 1,166 shares in the last quarter. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Option Care Health Price Performance

Shares of OPCH stock opened at $30.92 on Friday. The firm has a market cap of $5.26 billion, a P/E ratio of 25.98, a P/E/G ratio of 2.20 and a beta of 1.31. The firm has a fifty day moving average of $25.16 and a two-hundred day moving average of $27.91. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $34.63.

Insider Activity at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. acquired 43,000 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was purchased at an average price of $22.54 per share, with a total value of $969,220.00. Following the completion of the acquisition, the director now directly owns 326,334 shares in the company, valued at $7,355,568.36. This trade represents a 15.18 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.64% of the stock is owned by corporate insiders.

Analyst Ratings Changes

OPCH has been the topic of several analyst reports. Barrington Research raised their target price on Option Care Health from $32.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, January 14th. JMP Securities reiterated a “market outperform” rating and set a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. Truist Financial decreased their target price on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on shares of Option Care Health from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, UBS Group began coverage on shares of Option Care Health in a research report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price objective for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.25.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.